コクランジャパン,
Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for…
Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for…
Koja kombinacija inhalirajućih lijekova je sigurna i djelotvorna za liječenje kronične opstruktivne bolesti pluća (KOPB)? Kronič…
COCHRANE REVIEWS: "Para el tratamiento de la EPOC, LAMA + LABA tiene menos exacerbaciones, una mejoría mayor del FEV1, un…
production (fluids from the lungs, i.e. phlegm), and difficulty breathing. It is now possible to give two types of medicine…
Review findings support the recently updated GOLD guidance http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-pre…
Studies were mainly sponsored. Overall we judged the evidence to be of low to moderate quality. ow.ly/GfYl308WLmJ
Review included 11 studies on 9839 people. Most people had moderate to severe COPD, without recent exacerbations. ow.ly/GfYl308WL…
New #CochraneEvidence: LAMA+ LABA versus LABA +ICS for stable COPD #Cochrane #SystematicReview #COPD http://ow.ly/GfYl308WLmJ